Japan

In Japan, health products including pharmaceuticals, medical devices, diagnostics, and digital health solutions are regulated by the Pharmaceuticals and Medical Devices Agency (PMDA) under the authority of the Ministry of Health, Labour and Welfare (MHLW). The primary governing legislation is the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Pharmaceutical and Medical Device Act, PMD Act), first enacted in 1943 and substantially revised in 2014 and again in 2020. The PMDA conducts scientific review of applications while the MHLW grants formal marketing approval (Shonin). Products are classified by risk level, and all require either full approval or certification (Ninsho) depending on device class, with in vitro diagnostics and software as a medical device (SaMD) subject to dedicated regulatory pathways introduced under recent reforms.

Applicants must submit a Common Technical Document (CTD) dossier conforming to ICH guidelines, as Japan is a founding member of the International Council for Harmonisation (ICH). A Marketing Authorization Holder (MAH) domiciled in Japan is mandatory; foreign manufacturers without a local legal entity must appoint a licensed domestic MAH to hold the approval and bear regulatory responsibility. Japan has historically required domestic bridging studies or additional clinical data for foreign-originated products, though the MHLW has progressively relaxed these requirements to reduce drug lag. Key recent reforms include the 2020 PMD Act amendment, which established a bespoke conditional approval pathway for regenerative medicines and digital therapeutics, introduced a phased approval mechanism for innovative products with real-world evidence requirements post-approval, and strengthened post-market surveillance (GPSP and GVP) obligations. The PMDA also operates a consultation and strategy meeting system (RS Strategy Meetings) to guide applicants, particularly for novel modalities such as AI-based diagnostics and combination products.

Public procurement of health products in Japan is centrally coordinated through the MHLW, with pricing and reimbursement governed by the National Health Insurance (NHI) system administered under the Social Insurance Medical Fee Payment Fund and the National Federation of Health Insurance Societies. Japan operates a universal health insurance framework in which the MHLW sets the NHI Drug Price List (Yakka Kijun) and the Medical Device Reimbursement Price List (Tokutei Chiryo-zai) through biennial revisions, historically updated every two years and shifting to annual revisions from 2021 onward for pharmaceuticals. Hospitals and clinics procure products at negotiated prices at or below the listed NHI price, creating a de facto price ceiling that shapes the entire market. Prefectural governments and public hospital networks conduct their own tendering processes for device and consumable procurement, often through group purchasing organizations (GPOs), while the national government directly manages procurement for certain public health programs including vaccination, tuberculosis control, and infectious disease countermeasures through the National Institute of Infectious Diseases (NIID) and designated stockpile programs.

The private sector constitutes a substantial share of the Japanese health market, with private hospitals, clinics, and pharmacy chains procuring products through distributors (primarily large wholesalers such as Medipal, Alfresa, and Suzuken) operating under negotiated contracts. Japan is a high-income OECD member and does not participate in donor-funded procurement mechanisms such as those managed by UNICEF Supply Division, the Global Fund, USAID, or Gavi; all procurement is domestically financed through public insurance premiums, government budgets, and out-of-pocket patient contributions. Japan does maintain explicit policies encouraging domestic manufacturing and supply chain resilience, particularly following COVID-19 disruptions: the government introduced subsidies and strategic incentives under the Economic Security Promotion Act (2022) to onshore production of critical medical countermeasures, active pharmaceutical ingredients (APIs), and medical devices deemed essential to national security. Foreign manufacturers seeking market access are strongly advised to establish local production, warehousing, or at minimum a robust domestic distribution partnership to align with these strategic preferences and to meet cold-chain and post-market traceability requirements under Japanese Good Distribution Practice (GDP) guidelines.